HER-2 Predicts Complete Pathologic Response to Chemo Neoadjuvant Chemotherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 2
Volume 10
Issue 2

The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.

Optimal Care for HER2+ Breast Cancer

An interactive case challenge activity.

The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.

Go to Activity

Articles in this issue
Activated T Cells Can Alter Behavior of Leukemic B Cells
Response Continues for at Least 8 Months with Ibritumomab Tiuxetan
Chemotherapy Without Methotrexate Achieves Superb Results in Children With NHL
Iodine I 131 Tositumomab Induces Response in 70% of Patients Progressing After Rituximab
Synthetic Anthracycline Produces High Response Rates in SCLC
Ibritumomab Tiuxetan Produces 73% Response Rate in B-cell NHL
Rituximab Produces Clinical Responses in Even Steroid-Refractory Idiopathic Thrombocytopenic Purpura
G-CSF Might Prolong Rituximab Responses in NHL
Use of CAD Increases the Early Detection of Breast Cancer by 20%
Rituximab Plus Fludarabine May Be Good Alternative to Rituximab Plus CHOP
Student Cigarette Smoking Falls Significantly
Injectable COX-2 Inhibitor Effective in Postsurgery Pain
Patients’ Exercise Needs May Differ After Cancer Therapy
HAART Improves Survival in HIV-Positive NHL Patients
Liposomal Tretinoin Produces Impressive Responses in Refractory B-cell and T-cell Lymphomas
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Related Content
Oncologic outcomes from a real-world analysis appear to be comparable with those observed in the sentinel lymph node biopsy arm of the SOUND trial.

Real-World Data Support SLNB Omission in HR+ HER2– Breast Cancer

April 11th 2024
Article

Oncologic outcomes from a real-world analysis appear to be comparable with those observed in the sentinel lymph node biopsy arm of the SOUND trial.

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast Cancer

January 15th 2024
Podcast

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

Young patients with breast cancer were more likely to be the reason for diagnostic delays vs system delays, partly due to less concern for their symptoms.

Diagnostic Delays in Younger Women With Breast Cancer Are Mostly Patient-Related

April 11th 2024
Article

Young patients with breast cancer were more likely to be the reason for diagnostic delays vs system delays, partly due to less concern for their symptoms.

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

January 8th 2024
Podcast

Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.

Utidelone injection may cross the blood-brain barrier and help treat patients with breast cancer brain metastases.

Novel Injection Earns FDA ODD in Breast Cancer Brain Metastases

April 3rd 2024
Article

Utidelone injection may cross the blood-brain barrier and help treat patients with breast cancer brain metastases.

Data from the phase 3 TROPION-Breast01 trial support the biologics license application for datopotamab deruxtecan in hormone receptor–positive, HER2-negative breast cancer.

FDA Accepts BLA for Dato-DXd in Metastatic HR+/HER2– Breast Cancer

April 2nd 2024
Article

Data from the phase 3 TROPION-Breast01 trial support the biologics license application for datopotamab deruxtecan in hormone receptor–positive, HER2-negative breast cancer.